Format

Send to:

Choose Destination
See comment in PubMed Commons below
Cell Cycle. 2010 Apr 15;9(8):1480-6. Epub 2010 Apr 15.

SOX2 in squamous cell carcinoma: amplifying a pleiotropic oncogene along carcinogenesis.

Author information

  • 1IGBMC, Institut de Génétique et de Biologie Moléculaire et Cellulaire, Département de Biologie du Cancer, INSERM U964, CNRS-Université de Strasbourg UMR 7104, Illkirch, France. hussenet@igbmc.fr

Abstract

SOX2 is a master pluripotency controller that was recently identified as a novel major oncogene, recurrently amplified and activated in Squamous Cell Carcinoma (SCC). These studies have used a similar strategy of chromosomal aberrations screening to identify the SOX2 locus as one of the most frequently amplified site over the SCC genome. They have further highlighted the recurrent SOX2 activation and its necessary role for squamous cell survival. Finally, they showed that SOX2 is also involved in the early steps of lung SCC, as participating to transform human bronchial epithelial cells. Furthermore, SOX2 overexpression can induce the expression of the squamous markers p63 and keratin 6, supporting the idea that SOX2 might be implicated in SCC differentiation. In addition, SOX2 overexpression stimulates lung squamous cell migration. However, neither study assessed the impact of the recurrent activation of SOX2 in advanced primary tumors nor how SOX2 may mechanistically participate to tumor progression and aggressiveness. Here we present these studies and additional data from integrative transcriptomic analyses of primary lung SCC that altogether shed new light and open new exciting perspectives on the multiples roles that SOX2 exerts all along SCC carcinogenesis.

PMID:
20372069
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Write to the Help Desk